Chronic obstructive pulmonary disease

34 trials 6 recruiting MedDRA PT
34 Registered trials
6 Recruiting
16 Unique sponsors
33 Unique IMPs
30 Commercial trials
Drug classes (ATC)
— ATC code not specified 26
R Respiratory (ATC R) 7
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 26 substances
Monoclonal antibody 4 substances
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (immune) 1 substance
Statin 1 substance
Phase III: 12 Phase II: 4 Phase I/II: 2 Phase III/IV: 1 Phase IV: 4 Phase I: 1 Phase I (Other): 7 Other: 3

Filter these 34 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 34 trials

Phase III

12 trials
  • AstraZeneca AB Commercial
    TOZORAKIMAB
    2022-501063-41-00 17 countries 2023 n=802
    Ended
  • AstraZeneca AB Commercial
    BENRALIZUMAB
    2022-503050-39-00 13 countries 2019 n=236
    Ended
  • AstraZeneca AB Commercial
    TOZORAKIMAB
    2023-503571-19-00 11 countries 2022 n=479
    Ended
  • AstraZeneca AB Commercial
    TOZORAKIMAB
    2023-503572-24-00 6 countries 2022 n=350
    Ended
  • AstraZeneca AB Commercial
    TOZORAKIMAB
    2023-505543-39-00 12 countries 2024 n=480
    Ended
  • AstraZeneca AB Commercial
    TEZEPELUMAB
    2024-517457-27-00 9 countries 2025 n=293
    Recruiting
  • AstraZeneca AB Commercial
    TEZEPELUMAB
    2024-517458-90-00 7 countries 2025 n=187
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ASTEGOLIMAB
    2022-502234-70-00 16 countries 2023 n=683
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2023-508085-15-00 18 countries 2024 n=247
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2024-512012-21-00 12 countries 2021 n=747
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2024-512013-41-00 8 countries 2021 n=686
    Ended
  • Medical University Of Bialystok Academic
    ATORVASTATIN
    2024-516714-37-00 1 country 2022 n=480
    Ended

Phase II

4 trials
  • Aer Therapeutics Inc. Commercial
    6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE
    2025-523020-50-00 3 countries 2026 n=90
    Recruiting
  • AstraZeneca AB Commercial
    AZD6793
    2025-520473-40-00 8 countries 2025 n=314
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2024-512007-39-00 4 countries 2022 n=65
    Ended
  • Upstream Bio Inc. Commercial
    HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST CRLF2
    2025-520488-42-00 11 countries 2025 n=287
    Ended

Phase I/II

2 trials
  • Arrowhead Pharmaceuticals Inc. Commercial
    ADS-013
    2024-514809-67-00 2 countries 2023 n=32
    Ended
  • Centre Hospitalier Universitaire Grenoble Alpes Academic
    IMP not specified
    2024-516085-11-00 1 country n=24
    Pending

Phase III/IV

1 trial
  • AstraZeneca AB Commercial
    BUDESONIDE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE, BUDESONIDE
    2022-502274-16-00 2 countries 2023 n=160
    Ended

Phase IV

4 trials
  • AstraZeneca AB Commercial
    BUDESONIDE, GLYCOPYRRONIUM BROMIDE, FORMOTEROL FUMARATE DIHYDRATE
    2025-521987-37-00 1 country 2025 n=20
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    DUPILUMAB; SALBUTAMOL
    2025-521268-37-00 10 countries 2025 n=184
    Recruiting
  • ASST Fatebenefratelli Sacco Academic
    ERDOSTEINE
    2025-524821-42-00 1 country n=30
    Pending
  • Fundacio Privada Mon Clinic Barcelona Academic
    ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE; FORMOTEROL FUMARATE DIHYDRATE; FORMOTEROL FUMARATE DIHYDRATE, ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE, ACLIDINIUM BROMIDE; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE, INDACATEROL MALEATE; INDACATEROL; OLODATEROL; SALMETEROL; SALMETEROL XINAFOATE; TIOTROPIUM; TIOTROPIUM BROMIDE; TIOTROPIUM BROMIDE MONOHYDRATE; TIOTROPIUM, OLODATEROL; UMECLIDINIUM BROMIDE; UMECLIDINIUM BROMIDE, FLUTICASONE FUROATE, VILANTEROL; UMECLIDINIUM BROMIDE, VILANTEROL
    2023-507304-32-00 1 country 2024 n=1,028
    Ended

Phase I

1 trial
  • Glaxosmithkline Research & Development Limited Commercial
    IMP not specified
    2023-506880-32-01 1 country 2025 n=55
    Ended

Phase I (Other)

7 trials
  • AstraZeneca AB Commercial
    IMP not specified
    2023-509002-30-00 1 country 2024 n=16
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    IMP not specified
    2023-507300-30-00 1 country 2024 n=24
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    IMP not specified
    2024-516475-32-00 1 country 2025 n=24
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    IMP not specified
    2024-516861-35-00 1 country 2025 n=64
    Ended
  • Epiendo Pharmaceuticals ehf. Commercial
    IMP not specified
    2023-506345-34-00 1 country 2023 n=36
    Ended
  • Epiendo Pharmaceuticals ehf. Commercial
    IMP not specified
    2024-516187-29-00 1 country 2025 n=65
    Ended
  • Laboratorios Lesvi S.L. Commercial
    IMP not specified
    2025-522412-16-00 1 country n=75
    Pending

Other

3 trials
  • Celon Pharma S.A. Commercial
    IMP not specified
    2024-514725-38-00 1 country 2025 n=40
    Ended
  • Respirent Pharmaceuticals Co. Ltd. Commercial
    IMP not specified
    2023-504789-48-00 1 country 2023 n=34
    Ended
  • Respirent Pharmaceuticals Co. Ltd. Commercial
    IMP not specified
    2023-505198-34-00 1 country 2023 n=34
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
AstraZeneca AB Commercial 11 Phase III/IV, Phase I (Other), Phase II, Phase III, Phase IV 4
Sanofi-Aventis Recherche & Developpement Commercial 5 Phase II, Phase III, Phase IV 1
Chiesi Farmaceutici S.p.A. Commercial 3 Phase I (Other) 0
Respirent Pharmaceuticals Co. Ltd. Commercial 2 Other 0
Epiendo Pharmaceuticals ehf. Commercial 2 Phase I (Other) 0
Glaxosmithkline Research & Development Limited Commercial 1 Phase I 0
Celon Pharma S.A. Commercial 1 Other 0
Laboratorios Lesvi S.L. Commercial 1 Phase I (Other) 0
Aer Therapeutics Inc. Commercial 1 Phase II 1
Upstream Bio Inc. Commercial 1 Phase II 0
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Arrowhead Pharmaceuticals Inc. Commercial 1 Phase I/II 0
Medical University Of Bialystok Academic 1 Phase III 0
ASST Fatebenefratelli Sacco Academic 1 Phase IV 0
Fundacio Privada Mon Clinic Barcelona Academic 1 Phase IV 0
Centre Hospitalier Universitaire Grenoble Alpes Academic 1 Phase I/II 0
New trials by year
2019
1
2021
2
2022
4
2023
7
2024
5
2025
11
2026
1
← All indication landscapes